#1leading
MYD88 L265P is the founding mutation driving constitutive NF-κB and BTK signaling in WM
85 studies·pathogenesis
90
evidence
Waldenström's Macroglobulinemia
Also known asWMLymphoplasmacytic Lymphoma with IgMWaldenström macroglobulinemia
Waldenström's macroglobulinemia is an indolent B-cell lymphoproliferative disorder characterised by bone marrow infiltration with clonal lymphoplasmacytic cells that secrete monoclonal IgM. First described by Jan Gösta Waldenström in 1944, the disease is defined molecularly by the MYD88 L265P somatic mutation, present in >90% of cases.
Data sourced from 34 published studies with evidence grading (A–D). Last reviewed . Not medical advice.
Pathophysiology✓Well understood
Treatment✓Effective options available
Genetic basis○Well characterised
Research activity
34 studies·0 active trials·2001–2025
Epidemiology
- Total cases
- Unknown
- Mean onset
- 71 years
- Onset range
- 40–90 years
- Sex ratio (M:F)
- 2:1
- Diagnostic delay
- ~1 years
- Discovered
- 1944 (Jan Gösta Waldenström)
- Prevalence
- 3.8 per million person-years
- Classification
- Hematologic, Lymphoproliferative
Cardinal Features
7 key symptoms and signs
| Feature | Frequency | Category | Sources |
|---|---|---|---|
Fatigue / normochromic normocytic anemia Most common presenting symptom. Anemia results from bone marrow infiltration by lymphoplasmacytic cells, suppressing normal hematopoiesis. Hemoglobin typically 8-11 g/dL at presentation. | 80% | hematologic | |
Monoclonal IgM paraproteinemia Defining feature of WM. Serum IgM monoclonal protein produced by clonal lymphoplasmacytic cells. IgM concentration varies widely; levels correlate with hyperviscosity risk. | 100% | laboratory | |
Bone marrow infiltration Diagnostic requirement. Lymphoplasmacytic cells infiltrate bone marrow in diffuse, interstitial, or nodular pattern. Median marrow involvement ~60% at diagnosis. Causes cytopenias. | 100% | hematologic | |
Peripheral neuropathy IgM-related demyelinating neuropathy, often with anti-MAG antibodies. Typically slowly progressive, distal, symmetrical, sensorimotor. May also present as ataxic neuropathy. | 25% | neurologic | |
Hyperviscosity symptoms Caused by elevated pentameric IgM increasing blood viscosity. Manifests as oronasal bleeding, blurred vision (retinal venous engorgement), headache, dizziness, and neurologic dysfunction. Medical emergency requiring urgent plasmapheresis. | 15% | vascular | |
Constitutional symptoms (B symptoms) Fever, night sweats, and weight loss. Present in ~25% of patients at diagnosis. Weight loss is a distinguishing feature from marginal zone lymphoma in differential diagnosis. | 25% | systemic | |
Oronasal bleeding / mucosal hemorrhage Related to hyperviscosity and IgM interference with coagulation factors and platelet function. Epistaxis and gingival bleeding are classic presentations described by Waldenström in 1944. | 10% | hematologic |
Hypothesis Tracker
Competing explanations ranked by evidence weight
#2leading
CXCR4 WHIM-like mutations act as secondary drivers affecting bone marrow homing and drug resistance
40 studies·pathogenesis
78
evidence
#3leading
A two-hit model where MYD88 L265P provides the founding event and secondary mutations (CXCR4, ARID1A, TP53) shape disease phenotype
30 studies·pathogenesis
75
evidence
#4leading
The WM clone originates from a post-germinal center, IgM-committed B cell that has undergone somatic hypermutation but not class-switch recombination
15 studies·cell_of_origin
70
evidence
#5competing
The bone marrow microenvironment provides critical survival signals sustaining the WM clone
20 studies·pathogenesis
55
evidence
Open Questions
Why does MYD88 L265P specifically cause WM rather than other B-cell lymphomas?
MYD88 L265P is found in >90% of WM but also occurs in other lymphomas (ABC-DLBCL, primary CNS lymphoma) at lower frequencies. The factors that determine WM-specific phenotype vs. other lymphoma types remain unknown. Cell of origin and cooperating mutations likely play a role.
What is the precise role of CXCR4 mutations in treatment resistance and can they be therapeutically targeted?
CXCR4 WHIM-like mutations are present in ~30-40% of WM patients and are associated with inferior BTK inhibitor response. Both nonsense and frameshift subtypes exist with different clinical impacts. CXCR4 antagonists (mavorixafor) are being explored but clinical data is limited.
What is the optimal sequencing and combination of BTK inhibitors and other agents?
Covalent BTK inhibitors (ibrutinib, zanubrutinib) are highly effective first-line. Non-covalent BTK inhibitors (pirtobrutinib) show activity after covalent BTK inhibitor failure. Venetoclax combinations and fixed-duration strategies are under investigation. No consensus on optimal sequencing.
Can WM be cured, and what would a curative strategy look like?
WM is considered incurable with current therapies. Complete responses are rare even with the most effective regimens. BTK inhibitors require indefinite treatment. Fixed-duration combinations (ibrutinib + venetoclax) aim for deep responses but long-term cure is unproven. Allogeneic stem cell transplant can be curative but carries prohibitive toxicity for an indolent disease.
Why does Schnitzler syndrome sometimes progress to WM, and can progression be predicted or prevented?
Approximately 15-20% of Schnitzler syndrome patients develop WM or other lymphoproliferative disorders over 10+ years. Both diseases share MYD88 L265P in a subset of patients. Whether IL-1 blockade in Schnitzler prevents lymphoproliferative transformation is unknown.
Recent Updates
ASPEN trial final analysis: zanubrutinib vs ibrutinib in WM
Final analysis of the phase 3 ASPEN trial (Tam et al., JCO 2023) at 44.4-month median follow-up confirmed zanubrutinib superiority in tolerability over ibrutinib with VGPR+CR rates of 36.3% vs 25.3%. Zanubrutinib had significantly lower rates of atrial fibrillation (7.9% vs 23.5%), hypertension, and diarrhea. Both agents showed high overall response rates. Results support zanubrutinib as preferred covalent BTK inhibitor in WM.
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
Non-covalent (reversible) BTK inhibitor pirtobrutinib demonstrated meaningful activity in WM patients previously treated with covalent BTK inhibitors. The BRUIN trial established pirtobrutinib as a viable option after ibrutinib or zanubrutinib failure. Pirtobrutinib + venetoclax combination reported a 56% VGPR rate in early data, suggesting deep responses with combination approaches.
Ibrutinib + venetoclax fixed-duration combination in treatment-naive WM
Castillo et al. (Blood 2024) reported results of a novel fixed-duration ibrutinib + venetoclax combination in treatment-naive WM. This approach aims to achieve deep responses with time-limited therapy, avoiding the indefinite BTK inhibitor treatment paradigm. Represents a shift toward combination strategies seeking MRD negativity.
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
BTK degraders such as BGB-16673 and NX-5948 entered clinical trials for B-cell malignancies including WM. Unlike BTK inhibitors which require sustained binding, degraders eliminate the BTK protein entirely via the proteasome. This mechanism may overcome acquired resistance mutations at the BTK C481 binding site that limit covalent BTK inhibitor efficacy.
Genomics-guided treatment selection advances in WM
Treon et al. (Blood 2024) published a comprehensive genomics-guided approach to BTK inhibitor selection in WM. MYD88 and CXCR4 genotyping now informs first-line treatment choice. MYD88 wild-type patients (~5-10%) respond poorly to ibrutinib and may benefit from alternative approaches such as chemoimmunotherapy or venetoclax-based regimens.
Emerging CAR-T and bispecific antibody approaches for WM
Bispecific antibodies (epcoritamab, CD3xCD20) and antibody-drug conjugates (loncastuximab tesirine, anti-CD19 ADC) are under early investigation in WM and related lymphomas. CAR-T therapy targeting CD19 or CD20 represents a potential curative approach but data in WM specifically remain limited to case reports and early-phase trials.
MYD88 L265P identified as hallmark somatic mutation in WM
Treon et al. (2012, NEJM) identified the MYD88 L265P somatic mutation in 91% of WM patients by whole-genome sequencing. This activating mutation drives NF-kB and JAK-STAT signaling via constitutive TLR pathway activation, representing the most disease-specific oncogene in any B-cell malignancy and enabling molecular diagnostics and targeted therapy development.
Ibrutinib FDA-approved for WM as first targeted therapy
In January 2015, ibrutinib became the first FDA-approved targeted agent for WM based on a pivotal phase II trial showing 90.5% overall response rate in previously treated patients. Ibrutinib's efficacy is tied to dual inhibition of BTK and HCK signaling downstream of MYD88 L265P, transforming WM management from chemoimmunotherapy to oral targeted therapy.
CXCR4 WHIM-like mutations identified as second driver and ibrutinib resistance factor
Hunter et al. (2014) discovered activating CXCR4 mutations (homologous to WHIM syndrome variants) in 30-40% of WM patients. CXCR4 mutations confer relative ibrutinib resistance by sustaining AKT and ERK survival signaling, and are associated with higher IgM levels, symptomatic hyperviscosity, and slower treatment response. CXCR4 genotyping now guides treatment selection.
Zanubrutinib FDA-approved for WM
In August 2021, zanubrutinib received FDA approval for WM based on the ASPEN trial, making it the second BTK inhibitor approved for the disease. Zanubrutinib's more selective BTK inhibition profile results in fewer off-target effects including significantly lower rates of atrial fibrillation compared to ibrutinib, establishing it as a better-tolerated alternative.